Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Ophthalmology and OptometryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- TFOS DEWS II epidemiology report.Ocul Surf. 2017; 15: 334-365https://doi.org/10.1016/j.jtos.2017.05.003
- The definition and classification of dry eye disease: Report of the definition and classification subcommittee of the International Dry Eye Workshop (2007).Ocul Surf. 2007; 5: 75-92
- TFOS DEWS II management and therapy report.Ocul Surf. 2017; 15: 575-628https://doi.org/10.1016/j.jtos.2017.05.006
- TFOS DEWS II iatrogenic report.Ocul Surf. 2017; 15: 511-538https://doi.org/10.1016/j.jtos.2017.05.004
- The role of medications in causing dry eye.J Ophthalmol. 2012; 2012: 285851https://doi.org/10.1155/2012/285851
- Comparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren’s syndrome-related dry eye.Health Qual Life Outcomes. 2004; 2: 44https://doi.org/10.1186/1477-7525-2-44
- Reliability and validity of the ocular surface disease index.Arch Ophthalmol. 2000; 118: 615-621https://doi.org/10.1001/archopht.118.5.615
- Validation of the 5-item dry eye questionnaire (DEQ-5): discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses.Cont Lens Anterior Eye. 2010; 33: 55-60https://doi.org/10.1016/j.clae.2009.12.010
- Comparison of the performance of the dry eye questionnaire (DEQ-5) to the ocular surface disease index in a non-clinical population.Cont Lens Anterior Eye. 2021; : 101441https://doi.org/10.1016/j.clae.2021.101441
- Questionnaire assists in dry eye disease diagnosis. Four-question survey helps evaluate patients’ dry eye symptoms to improve screening.Ocul Surg News. 2012;
- Psychometric properties and validation of the standard patient evaluation of eye dryness questionnaire.Cornea. 2013; 32: 1204-1210https://doi.org/10.1097/ICO.0b013e318294b0c0
- TFOS DEWS II diagnostic methodology report.Ocul Surf. 2017; 15: 539-574https://doi.org/10.1016/j.jtos.2017.05.001
- Definition and diagnostic criteria of dry eye disease: historical overview and future directions.Invest Ophthalmol Vis Sci. 2018; 59: DES7-12https://doi.org/10.1167/iovs.17-23475
- Diagnosing the severity of dry eye: a clear and practical algorithm.Br J Ophthalmol. 2014; 98: 1168-1176https://doi.org/10.1136/bjophthalmol-2013-304619
- Imaging lid-parallel conjunctival folds with OCT and comparing its grading with the slit lamp classification in dry eye patients and normal subjects.Invest Ophthalmol Vis Sci. 2011; 52: 2945-2951https://doi.org/10.1167/iovs.10-5505
- Schirmer test after topical anesthesia and the tear meniscus height in normal eyes.Arch Ophthalmol. 1979; 97: 1082-1085https://doi.org/10.1001/archopht.1979.01020010536004
- Interpretation of tear film breakup.Arch Ophthalmol. 1977; 95: 445-448https://doi.org/10.1001/archopht.1977.04450030087010
- Tear film osmolarity and dry eye disease: a review of the literature.Clin Ophthalmol. 2015; 9: 2039-2047https://doi.org/10.2147/OPTH.S95242
- Matrix metalloproteinase 9 testing in dry eye disease using a commercially available point-of-care immunoassay.Ophthalmology. 2016; 123: 2300-2308https://doi.org/10.1016/j.ophtha.2016.07.028
- Abnormal protein profiles in tears with dry eye syndrome.Am J Ophthalmol. 2003; 136: 291-299https://doi.org/10.1016/s0002-9394(03)00203-4
- Tear film normalization test: a new diagnostic test for dry eyes.Cornea. 2006; 25: 1153-1157https://doi.org/10.1097/01.ico.0000240085.21105.51
- Review and analysis of grading scales for ocular surface staining.Ocul Surf. 2019; 17: 208-220https://doi.org/10.1016/j.jtos.2019.01.004
- Pharmacotherapy of dry eye.Expert Opin Pharmacother. 2011; 12: 325-334https://doi.org/10.1517/14656566.2010.518612
- Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women.Am J Clin Nutr. 2005; 82: 887-893https://doi.org/10.1093/ajcn/82.4.887
- n-3 Fatty acid supplementation for the treatment of dry eye disease.N Engl J Med. 2018; 378: 1681-1690https://doi.org/10.1056/NEJMoa1709691
- Vitamin D deficiency is associated with dry eye syndrome: a systematic review and meta-analysis.Acta Ophthalmol. 2020; 98: 749-754https://doi.org/10.1111/aos.14470
- Six-month effects of a thermodynamic treatment for MGD and implications of meibomian gland atrophy.Cornea. 2014; 33: 1265-1270https://doi.org/10.1097/ICO.0000000000000273
- Current and emerging therapeutic strategies for the treatment of meibomian gland dysfunction (MGD).Drugs. 2015; 75: 1177-1185https://doi.org/10.1007/s40265-015-0432-8
- Over the counter (OTC) artificial tear drops for dry eye syndrome.Cochrane Database Syst Rev. 2016; 2: CD009729https://doi.org/10.1002/14651858.CD009729.pub2
- Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects.Arch Ophthalmol. 1992; 110: 528-532https://doi.org/10.1001/archopht.1992.01080160106043
- Punctal occlusion for dry eye syndrome.Cochrane Database Syst Rev. 2017; 6: CD006775https://doi.org/10.1002/14651858.CD006775.pub3
- Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.Ophthalmology. 2000; 107: 631-639https://doi.org/10.1016/s0161-6420(99)00176-1
- Advances in dry eye disease treatment.Curr Opin Ophthalmol. 2019; 30: 166-178https://doi.org/10.1097/ICU.0000000000000569
- A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease.Clin Ophthalmol. 2018; 12: 1921-1929https://doi.org/10.2147/OPTH.S175065
- Dry eye treatment with topical cyclosporine 0.1% in chondroitin sulfate ophthalmic emulsion.Clin Ophthalmol. 2021; 15: 1979-1984https://doi.org/10.2147/OPTH.S308088
- Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05.Eye Contact Lens. 2014; 40: 289-296https://doi.org/10.1097/ICL.0000000000000049
- Lifitegrast: a novel drug for patients with dry eye disease.Ther Adv Ophthalmol. 2019; 11https://doi.org/10.1177/2515841419870366
- Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome.Ophthalmology. 1999; 106: 811-816https://doi.org/10.1016/S0161-6420(99)90171-9
- Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations.Cornea. 2010; 29: 781-788https://doi.org/10.1097/ICO.0b013e3181cda38f
- The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction.Korean J Ophthalmol. 2005; 19: 258https://doi.org/10.3341/kjo.2005.19.4.258
- Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study.Cornea. 2013; 32: 44-53https://doi.org/10.1097/ICO.0b013e318254205f
- Reflections on dry eye syndrome treatment: therapeutic role of blood products.Front Med. 2018; 5: 33https://doi.org/10.3389/fmed.2018.00033
- Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies.Acta Ophthalmol. 2015; 93: e605-e614https://doi.org/10.1111/aos.12710
- Plasma rich in growth factors for the treatment of dry eye from patients with graft versus host diseases.Eur J Ophthalmol. 2020; 30: 94-103https://doi.org/10.1177/1120672118818943
- Treatment of dry eye disease with autologous platelet-rich plasma: a prospective, interventional, non-randomized study.Ophthalmol Ther. 2017; 6: 285-293https://doi.org/10.1007/s40123-017-0100-z
- Long-term outcomes of punctal cauterization in the management of ocular surface diseases.Cornea. 2021; 40: 168-171https://doi.org/10.1097/ICO.0000000000002384
- Surgery of the conjunctiva.in: Dev Ophthalmol. vol. 41. KARGER, Basel2008: 138-158https://doi.org/10.1159/000131086
- Prospective evaluation of intense pulsed light and meibomian gland expression efficacy on relieving signs and symptoms of dry eye disease due to meibomian gland dysfunction.Clin Ophthalmol. 2017; 11: 817-827https://doi.org/10.2147/OPTH.S130706
- Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial.Ocul Surf. 2014; 12: 146-154https://doi.org/10.1016/j.jtos.2013.12.001
- Comparison of the iLUX and the LipiFlow for the Treatment of Meibomian Gland dysfunction and symptoms: a randomized clinical trial.Clin Ophthalmol. 2020; 14: 405-418https://doi.org/10.2147/OPTH.S234008
- New, targeted technology for treating the root cause of dry eye disease (DED).(MiBo Medical n.d. Avilable at:) (Accessed February 28, 2021)
- A prospective, post-market, multicenter trial (CHEETAH) suggested TEARCARE® system as a safe and effective blink-assisted eyelid device for the treatment of dry eye disease.Clin Ophthalmol. 2020; 14: 4551-4559https://doi.org/10.2147/OPTH.S285953
- Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction.Cornea. 2010; 29: 1145-1152https://doi.org/10.1097/ICO.0b013e3181d836f3
- Double-masked and unmasked prospective study of terpinen-4-ol lid scrubs with microblepharoexfoliation for the treatment of demodex blepharitis.Cornea. 2020; 39: 408-416https://doi.org/10.1097/ICO.0000000000002243
- Novel extranasal tear stimulation: pivotal study results.Transl Vis Sci Technol. 2020; 9: 23https://doi.org/10.1167/tvst.9.12.23
- Randomized, controlled, double-masked, multicenter, pilot study evaluating safety and efficacy of intranasal neurostimulation for dry eye disease.Invest Ophthalmol Vis Sci. 2019; 60: 147https://doi.org/10.1167/iovs.18-23984
- Efficacy and safety of OC-01 (Varenicline) nasal spray on signs and symptoms of dry eye disease: the ONSET-2 phase 3, randomized trial.Ophthalmology. 2021; S0161-6420: 00836-00838https://doi.org/10.1016/j.ophtha.2021.11.004
- Understanding neuropathic corneal pain--gaps and current therapeutic approaches.Semin Ophthalmol. 2016; 31: 59-70https://doi.org/10.3109/08820538.2015.1114853
- EyePrintPRO therapeutic scleral contact lens: indications and outcomes.Can J Ophthalmol. 2018; 53: 66-70https://doi.org/10.1016/j.jcjo.2017.07.026
- Role of amniotic membrane transplantation in ocular surface disorders.Nepal J Ophthalmol. 2010; 2: 145-153https://doi.org/10.3126/nepjoph.v2i2.3722
- Treatment outcomes in the DRy Eye amniotic membrane (DREAM) study.Clin Ophthalmol. 2018; 12: 677-681https://doi.org/10.2147/OPTH.S162203
- Tear dynamics and corneal confocal microscopy of subjects with mild self-reported office dry eye.Ophthalmology. 2011; 118: 902-907https://doi.org/10.1016/j.ophtha.2010.08.033
- Corneal nerve structure and function in patients with non-sjogren dry eye: clinical correlations.Invest Ophthalmol Vis Sci. 2013; 54: 5144-5150https://doi.org/10.1167/iovs.13-12370
- Changes in corneal epithelial layer inflammatory cells in aqueous tear-deficient dry eye.Invest Ophthalmol Vis Sci. 2010; 51: 122-128https://doi.org/10.1167/iovs.09-3629
- An instrument for quantifying meibomian lipid on the lid margin: the Meibometer.Curr Eye Res. 1993; 12: 247-254https://doi.org/10.3109/02713689308999470
- Infrared imaging of meibomian gland structure using a novel keratograph.Optom Vis Sci. 2012; 89: 788-794https://doi.org/10.1097/OPX.0b013e318253de93
- Meibography: a review of techniques and technologies.Saudi J Ophthalmol. 2012; 26: 349-356https://doi.org/10.1016/j.sjopt.2012.08.007
- In vivo findings of the bulbar/palpebral conjunctiva and presumed meibomian glands by laser scanning confocal microscopy.Cornea. 2005; 24: 985-988https://doi.org/10.1097/01.ico.0000160976.88824.2b
- Interferometry in the evaluation of precorneal tear film thickness in dry eye.Am J Ophthalmol. 2011; 151: 18-23.e1https://doi.org/10.1016/j.ajo.2010.07.019
- Tear interferometric patterns reflect clinical tear dynamics in dry eye patients.Invest Ophthalmol Vis Sci. 2016; 57: 3928-3934https://doi.org/10.1167/iovs.16-19788
- Predicting dry eye using noninvasive techniques of tear film surface assessment.Invest Ophthalmol Vis Sci. 2011; 52: 751-756https://doi.org/10.1167/iovs.10-5173
- Fluorophotometry as a diagnostic tool for the evaluation of dry eye disease.BMC Ophthalmol. 2006; 6: 20https://doi.org/10.1186/1471-2415-6-20
- Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study.Br J Ophthalmol. 2020; 104: 127-135https://doi.org/10.1136/bjophthalmol-2018-312470
- Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye.Clin Ophthalmol. 2013; 7: 1275-1285https://doi.org/10.2147/OPTH.S44688
- Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease.Invest Ophthalmol Vis Sci. 2014; 55: 5401-5409https://doi.org/10.1167/iovs.14-13924
- A two-week, randomized, double-masked study to evaluate safety and efficacy of lubricin (150 μg/mL) eye drops versus sodium hyaluronate (HA) 0.18% eye drops (Vismed®) in patients with moderate dry eye disease.Ocul Surf. 2017; 15: 77-87https://doi.org/10.1016/j.jtos.2016.08.004
- Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea. 2015; 34: 491-496https://doi.org/10.1097/ICO.0000000000000379
- Amniotic membrane extract and eye drops: a review of literature and clinical application.Clin Ophthalmol. 2018; 12: 1105-1112https://doi.org/10.2147/OPTH.S165553
- A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease.Cornea. 2021; 40: 1132-1140https://doi.org/10.1097/ICO.0000000000002622
- Early onset and broad activity of reproxalap in a randomized, double-masked, vehicle-controlled phase 2b trial in dry eye disease.Am J Ophthalmol. 2021; 226: 22-31https://doi.org/10.1016/j.ajo.2021.01.011
- Safety and efficacy of ALG-1007 topical ophthalmic solution – A synthetic peptide that regulates inflammation, in patients with dry eye disease: an exploratory phase I, open-label, single-center clinical study.AJOCT. 2020; 3: 10https://doi.org/10.25259/AJOCT_1_2020
- Probing the role of melanocortin type 1 receptor agonists in diverse immunological diseases.Front Pharmacol. 2018; 9: 1535https://doi.org/10.3389/fphar.2018.01535
- Azura Ophthalmics Announces Primary Endpoints Met in Phase 2 Trial of Investigational Treatment for Contact Lens Discomfort.(Available at:) (Accessed February 28, 2021)
- Novel diagnostics and therapeutics in dry eye disease.Adv Ophthalmol Optom. 2016; 1: 1-20https://doi.org/10.1016/j.yaoo.2016.03.016
Article info
Publication history
Published online: June 27, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
